ANN ARBOR, MI / ACCESSWIRE / September 14, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced the commercial launch of its newest assay - endogenous ACTH (eACTH) for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform..

ANN ARBOR，MI/ACCESSWIRE/2023年9月14日/Zomedica Corp.（NYSE American:ZOM）（'Zomedica'或'公司'），一家为伴侣动物提供诊断和治疗产品的兽医健康公司，今天宣布商业推出其最新测定-马血浆内源性ACTH（eACTH）-用于TRUFORMA临床生物传感器测试平台。。

Larry Heaton, Zomedica's Chief Executive Officer, commented, 'For the last two years the TRUFORMA diagnostic platform has brought novel point of care diagnostic capabilities to small animal veterinarians, including Feline Optimized TSH and canine endogenous ACTH assays. Now equine veterinarians can experience the reference lab accuracy and point of care convenience of the TRUFORMA diagnostic platform with our newest assay, eACTH for equine plasma.

Zomedica首席执行官Larry Heaton评论说：“在过去两年中，TRUFORMA诊断平台为小动物兽医带来了新颖的即时诊断能力，包括猫优化的TSH和犬内源性ACTH检测。现在，马兽医可以通过我们最新的检测方法-马血浆eACTH，体验TRUFORMA诊断平台的参考实验室准确性和即时护理便利性。

This assay enables equine veterinarians in the clinic or at the stall to diagnose equine Cushing's Disease, known clinically as pituitary pars intermedia dysfunction (PPID), and monitor positive patients as they titrate therapy. This new assay for the TRUFORMA instrument is an example of Zomedica's ongoing focus to meet the needs of clinical veterinarians in ways that promote both patient and practice health.'.

该试验使临床或摊位的马兽医能够诊断马库欣病，临床上称为垂体中间功能障碍（PPID），并在滴定治疗时监测阳性患者。这种针对TRUFORMA仪器的新检测方法是Zomedica持续关注的一个例子，以满足临床兽医的需求，促进患者和实践健康。

PPID or Cushing's disease is one of the most common endocrine disorders in horses and ponies. Left undiagnosed and untreated, quality of life for these animals will rapidly decline and their life expectancy will shorten.

PPID或库欣病是马和小马中最常见的内分泌失调之一。如果不加以诊断和治疗，这些动物的生活质量将迅速下降，预期寿命将缩短。

The measurement of baseline eACTH is widely accepted as the most effective way to help diagnose PPID and plays an essential role in disease management, but until now, to test eACTH levels, blood samples needed special handling and shipping to remote labs, risking sample degradation or even loss. The TRUFORMA eACTH assay for equine plasma will offer equine veterinarians the ability to diagnose and screen for PPID as well as monitor patients being treated for PPID in their own labs or even stall side in minutes.

基线eACTH的测量被广泛接受为帮助诊断PPID的最有效方法，并在疾病管理中发挥重要作用，但到目前为止，为了测试eACTH水平，血液样本需要特殊处理并运送到远程实验室，冒着样本风险退化甚至损失。马血浆的TRUFORMA eACTH测定将为马兽医提供诊断和筛查PPID的能力，以及监测在他们自己的实验室中接受PPID治疗的患者，甚至在几分钟内停滞。

The TRUFORMA device, being compact, easy to use, and durable, is a great fit for the unique challenges that face equine practitioners..

TRUFORMA设备紧凑，易于使用且耐用，非常适合马从业者面临的独特挑战。。

Adrian Lock, Vice President & General Manager of Zomedica, addressed the business opportunity for the Company, 'There are approximately 2,500 Equine Veterinary practices in the U.S. and currently over 1,200 of them routinely use our PulseVet shock wave system. This will allow us to rapidly engage with the Equine Veterinary community to quickly bring this vital screening technology to patients.

Zomedica副总裁兼总经理Adrian Lock为该公司提供了业务机会，“美国大约有2500种马兽医实践，目前超过1200种常规使用我们的PulseVet冲击波系统。这将使我们能够快速与马兽医界合作，快速为患者带来这项重要的筛查技术。

We anticipate this will become a tool used by Equine veterinarians daily as they care for the millions of horses in the US susceptible to PPID.'.

我们预计这将成为马兽医每天使用的工具，因为他们照顾美国数百万匹易受PPID影响的马。

For more information on Zomedica please visit www.zomedica.com.

有关Zomedica的更多信息，请访问www.Zomedica.com。

About Zomedica

关于Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health.

Zomedica位于密歇根州安阿伯市，是一家兽医健康公司，通过关注临床兽医未满足的需求，为伴侣动物创造产品。Zomedica的产品组合将包括强调患者健康和实践健康的创新诊断和医疗设备。

It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com..

Zomedica的使命是为兽医提供提高生产力和增加收入的机会，同时更好地为动物提供护理服务。欲了解更多信息，请访问www.ZOMEDICA.com。。

Follow Zomedica

跟随Zomedica

Email Alerts: http://investors.zomedica.com

电子邮件警报：http://investors.zomedica.com

LinkedIn: https://www.linkedin.com/company/zomedica

LinkedIn: https://www.linkedin.com/company/zomedica

Facebook: https://m.facebook.com/zomedica

Facebook：https://m.facebook.com/zomedica

Twitter: https://twitter.com/zomedica

Twitter：https://twitter.com/zomedica

Instagram: https://www.instagram.com/zomedica_inc

Instagram: https://www.instagram.com/zomedica_inc

Cautionary Statement Regarding Forward-Looking Statements - Safe Harbor

关于前瞻性陈述的警示声明-安全港

Except for statements of historical fact, this news release contains certain 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate' and other similar words, or statements that certain events or conditions 'may' or 'will' occur and include statements relating to our expectations regarding future results.

除历史事实陈述外，本新闻稿还包含适用证券法含义内的某些“前瞻性信息”或“前瞻性陈述”（统称为“前瞻性信息”）。前瞻性信息通常以“计划”，“期望”，“项目”，“意图”，“相信”，“预期”，“估计”和其他类似词语等词语为特征，或某些事件或条件“可能”或“将”发生，并包括与我们对未来结果的期望相关的陈述。

Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information..

虽然我们认为前瞻性信息中反映的期望是合理的，但不能保证这种期望证明是正确的。我们无法保证未来的结果，表现或成就。因此，没有任何迹象表明实际取得的成果全部或部分与前瞻性信息中所述的成果相同。。

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition..

前瞻性信息基于声明发布之日的管理层意见和估计，包括经济增长，公司产品需求，公司生产和销售产品的能力，我们预算资本的充足性和运营支出，我们的战略合作伙伴对我们商业协议下的义务感到满意，我们实施业务计划和成本控制工作的能力以及COVID-19对我们业务，结果和财务状况的影响。。

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to:veterinary acceptance of our products in the TRUFORMA® eACTH product; costs associated with manufacturing our products; the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensin.

我们的前瞻性信息受到各种风险和不确定性以及其他可能导致实际事件或结果与前瞻性信息中预期的实质性差异的因素的影响。可能导致结果与前瞻性信息中表达的结果有重大差异的一些风险和其他因素包括但不限于：兽医接受我们在TRUFORMA®eACTH产品中的产品；与制造我们的产品相关的成本；普遍接受的会计原则的应用非常复杂，涉及许多主观假设，估计和判断，我们的战略和业务计划是否会产生预期收益的不确定性；开发工作的时间和结果以及验证和验证研究的不确定性；商业化努力的时间和结果以及商业化努力的成本存在不确定性，包括开发内部销售人员和管理我们的增长的成本；我们根据客户需求提供产品的能力存在不确定性；关于任何所需监管批准的可能性和时间以及资本的可用性和成本的不确定性；识别和开发新产品和技术并取得商业成功的能力；相关产品竞争；维持和提高产品和服务质量所需的支出水平；技术变化和法律法规的变化；我们确保和维护战略关系的能力；我们的战略合作伙伴履行我们商业协议规定的义务，包括产品制造义务；与许可证和许可证有关的风险。

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation.

本新闻稿中包含的前瞻性信息受到本警示性声明的明确限制。除适用证券立法另有要求外，我们不承担更新任何前瞻性信息的责任，以使这些信息符合实际结果或我们的期望变化。

Readers are cautioned not to place undue reliance on forward-looking information..

警告读者不要过分依赖前瞻性信息。。

Contact:

联系方式：

Dave Gentry

戴夫·金特里

RedChip Companies Inc.

RedChip公司。

1-800-RED-CHIP (733-2447)

1-800红片（733-2447）

Or 407-491-4498

或407-491-4498

ZOM@redchip.com

ZOM@redchip.com

SOURCE: Zomedica Corp.

资料来源：Zomedica Corp。

View source version on accesswire.com:

在AccessWire.com上查看源版本：

https://www.accesswire.com/783875/zomedica-announces-expansion-of-market-opportunity-for-truformar-diagnostic-platform-with-launch-of-first-and-only-point-of-care-eacth-assay-for-diagnosis-and-management-of-cushings-disease-in-horses

https://www.accesswire.com/783875/zomedica-announces-expansion-of-market-opportunity-for-truformar-diagnostic-platform-with-launch-of-first-and-only-point-of-care-eacth-assay-for-diagnosis-and-management-of-cushings-disease-in-horses